Concepedia

First‐in‐human, randomized dose‐escalation study of the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of PF‐06480605 in healthy subjects

Christopher Banfield, Dan Rudin, Indranil Bhattacharya, Kosalaram Goteti, Gang Li, Mina Hassan‐Zahraee, Lisa Brown, Kenneth E. Hung, Sylvester Pawlak, Christopher Lepsy

British Journal of Clinical Pharmacology · 2019 · 29 citations · 34 references

DOIFull text

Open access

Abstract

PF-06480605 was generally well tolerated, and binding of soluble TL1A was maintained throughout the dose interval, supporting further study of PF-06480605 in patients with IBD and other inflammatory conditions.

References

34

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

Jean‐Frédéric Colombel, William J. Sandborn, Walter Reinisch et al. · New England Journal of Medicine · 2010 · 3.1K citations · Full text

TL1A Is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T Cell Costimulator

Thi-Sau Migone, Jun Zhang, Xia Luo et al. · Immunity · 2002 · 631 citations · Full text

, , +9

Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years — United States, 2015

James M. Dahlhamer, Emily P. Zammitti, Brian Ward et al. · MMWR Morbidity and Mortality Weekly Report · 2016 · 621 citations · Full text

, , +16

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

Konstantinos Κarmiris, Gilles Paintaud, Maja Noman et al. · Gastroenterology · 2009 · 477 citations · Full text

, , +11

Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010

Raina Shivashankar, William J. Tremaine, William S. Harmsen et al. · Clinical Gastroenterology and Hepatology · 2016 · 451 citations · Full text

, , +6